|Printable version||E-mail this to a friend|
CJEU: Uber can be required to obtain the necessary transport licences & authorisations under national law
According to Advocate General Szpunar, the Uber electronic platform, whilst innovative, falls within the field of transport: Uber can thus be required to obtain the necessary licences and authorisations under national law Uber cannot claim the benefit of the principle of the freedom to provide services guaranteed by EU law for information society services.
Latest News from
EC receives mandate to begin negotiations with the UK23/05/2017 16:10:00
The EC welcomes the Council's decision to authorise the opening of the Article 50 negotiations with the UK and to nominate the EC as Union negotiator. The EC also welcomes the adoption of the first set of negotiating directives.
‘European Investigation Order’ will help authorities to fight crime and terrorism23/05/2017 15:05:00
The "European Investigation Order" has entered into force. It simplifies the work of judicial authorities when they request evidence located in another EU country.
European Semester 2017 Spring Package: EC issues country-specific recommendations23/05/2017 14:10:00
Member States should use the window of opportunity offered by the economic recovery to pursue structural reforms, boost investment and strengthen their public finances. Priorities vary across the EU but further efforts across the board are essential to achieve more inclusive, robust and sustainable growth.
Public access to Council documents: 2016 report23/05/2017 13:20:00
Over 350 000 documents are listed in the Council's register, and over 70% of these are public and can be downloaded for free. That is one of the key points in the Council's 2016 report on access to documents which was approved by the Council on 22 May 2017.
New EudraVigilance system for collection & monitoring of suspected adverse reactions23/05/2017 12:38:00
The EMA will launch a new & improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new version will go live on 22 November 2017.